Skip to main content

Advertisement

Table 2 Continuous outcome measures

From: Combined use of topical intraarticular tranexamic acid and rivaroxaban in total knee arthroplasty safely reduces blood loss, transfusion rates, and wound complications without increasing the risk of thrombosis

  Rivaroxaban only (n = 52) Rivaroxaban + IA TXA (n = 52) p-value
Total drain output (mL) 1021.4 (893.9–1148.9) 419.1 (349.9–488.3) < 0.001
Nadir Hb during hospital stay (mL) 8.2 (7.9–8.6) 9.0 (8.8–9.3) < 0.001
Maximum decrease in Hb (g/dL) 4.2 (3.9–4.6) 3.6 (3.1–4.0) 0.015
Total blood loss (mL) 1260.1 (1168.7–1351.6) 1008.2 (910.3–1106.2) < 0.001
  1. All values presented as means (95% confidence interval) and compared using independent t-tests